Ibrahim Hanouneh is a Gastroenterology physician affiliated with Abbott Northwestern Hospital. OpenAlex indexes 164 publications with 4,367 citations (h-index 27).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 1st St SW
Rochester, MN 55905
Telephone
507-284-2511Provider last certified this registry record 29 Oct 2020.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Madrigal PharmaceuticalsProgram year20242 payments
- Novo Nordisk IncProgram year20241 payment
- ABBVIE INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
66.9%TNF inhibitor63.2%Infliximab100%Part B, office-administered≥12 patientsPurine Antimetabolite3.8%Azathioprine100%Part D≥20 patientsMetabolism & gastrointestinal
17.8%Bile Acid5.1%Ursodiol100%Part D≥28 patientsOsmotic Laxative4.8%Lactulose57%Constulose28%Gavilyte-G15%Part D<11 patients+ 4 more classes in this area
Cardiovascular
9.8%Loop diuretic4.3%Furosemide100%Part D≥29 patientsAldosterone antagonist (MRA)3.9%Spironolactone100%Part D≥29 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis
Clinical Gastroenterology and Hepatology
2020 - Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?
Expert Opinion on Investigational Drugs
2020 - Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?
Clinical and Molecular Hepatology
2019 - A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis
Scandinavian Journal of Gastroenterology
2019 - Effectiveness of venous thromboembolism prophylaxis in patients with liver disease
World Journal of Hepatology
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Miedema, MD
Abbott Northwestern Hospital
Erik Schelbert, MD
Abbott Northwestern Hospital
Joao Cavalcante, MD
Abbott Northwestern Hospital
Vinayak Bapat, MD
Abbott Northwestern Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”